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INTRODUCTION
Respiratory viruses, predominantly rhinovirus (RV), are the 
most common cause of asthma exacerbation. Respiratory tract 
infections caused by respiratory viruses are associated with ap-
proximately 80% of asthma exacerbation episodes, in both 
adults and children1-6 and RV is detected in approximately 60% 
of patients with asthma exacerbations.1 Patients with asthma 
are more susceptible to viral infections.7 Bronchial epithelial 
cells seem to be critical for the development of the innate im-
mune response to virus infection,8 and some studies show a re-
duced generation of type I and III interferons (IFNs) in RV-in-
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fected bronchial epithelial cells (HBECs) from patients with 
asthma, reflecting an impaired antiviral response.9-12 Inade-
quate response to rhinovirus infection was also detected in oth-
er cells, such as alveolar macrophages,11 bronchoalveolar la-
vage cells,13 and blood mononuclear cells from asthma pa-
tients.10,14,15 Similarly, reduced in vitro immune response to viral 
infections was observed in asthmatic children16-18 and has been 
implicated in increased susceptibility to viral infections.19,20 
However, several other studies did not confirm reduced expres-
sion or release of IFNs in response to viral infection in HBECs 
from patients with asthma.21-25 Several intracellular mecha-
nisms are involved in the regulation of IFNs production by 
HBECs in response to virus infections,8 but activation of IFN-
regulatory factors (IRFs) seems to play a central role. The IRF 
family includes IRF-1 to IRF-9, among which IRF-3 is expressed 
constitutively, while IRF-7 expression is induced by lipopoly-
saccharide and virus infection. Both IRF-3 and IRF-7 activate 
transcription of the genes for IFN-β, IFN-α1, and RANTES, 
while IRF-7 alone positively regulates genes for IFN-α4, IFN-α7, 
and IFN-α14.26 Structural cells, such as epithelial cells, produce 
IFN-β rather than IFN-α and IRF-3, which are essential for viral 
induction of IFN-β. IFN-α, is mainly produced by leukocytes 
and while IRF-7 can effectively induce genes for both IFN-α and 
IFN-β.27,28 IRF-7 is mainly associated with IFN-α induction, as it 
is constitutively expressed in subsets of leukocytes, such as 
dendritic cells. The regulation of type III IFNs by viruses has 
been reported to also make use of IRF-3 and IRF-7.29,30 IFN-γ-
induced protein 10 (CXCL10, IP-10) and RANTES (CCL5) are 
released in great quantities by bronchial epithelial cells.31 It has 
been suggested that IP-10 release is specific to acute virus-in-
duced asthma.32,33 In contrast to rhinoviruses which have been 
extensively studied, immune response to parainfluenza viruses 
in HBEC from asthmatic patients has not been reported. Para-
influenza virus type 3 (PIV3) is a pleomorphic enveloped virus 
with nonsegmented negative-strand RNA genome (comple-
mentary to mRNA) which belongs to the Paramyxoviridae fam-
ily and the Respirovirus genus. PIV3 is a common respiratory vi-
rus causing upper and lower respiratory tract illnesses, includ-
ing common cold, laryngotracheobronchitis (i.e. croup), tra-
cheobronchitis, bronchiolitis, and pneumonia, in both children 
and adults. Although these infections are rather mild in healthy 
individuals, they may lead to exacerbation in patients with 
asthma or COPD.34
In order to better understand determinants of variability in 
immune responses to respiratory virus infections of airway epi-
thelial cells in patients with asthma, we evaluated the response 
to PIV3 and RV1B infection in primary bronchial epithelial cells 
cultured from the phenotypically heterogeneous group of asth-
matics and healthy controls. These studies are necessary to as-
certain the relative efficacy of inhaled IFN therapy for asthma35 
and the role of atopy in influencing anti-viral immunity to re-
spiratory viruses.
MATERIALS AND METHODS
Study subjects
Ten patients (6 atopic and 4 non-atopic) with bronchial asth-
ma diagnosed according to the GINA criteria were recruited 
from the the Department of Pulmonology and Allergology. All 
patients suffered from persistent asthma and were treated with 
inhaled corticosteroids, which were withdrawn 24 hours before 
bronchial sampling. Asthma severity was assessed according to 
the GINA guideline36 and asthma control with the Asthma Con-
trol Test (ACT).37 Atopy was defined as the presence of at least 1 
positive skin response (wheal diameter >3 mm) to skin-prick 
tests (SPTs) performed with the panel of 14 common inhalant 
Table 1. Clinical characteristics of  subjects
Healthy subjects Patients with asthma Patients with atopic asthma Patients with non-atopic asthma
Subjects (n) 9 10 6 4
Age 31.78±14.62 33.50±9.62 29.00±6.10 40.25±10.69
Male/female 5/4 5/1 2/2
ACT n/a 17.20±6.39 19.17±6.89 14.25±4.92
ICS daily dose (μg/day) n/a 1,388.00±1,458.65 513.33±403.52 900.00±637.91
ICS dose (μg)/day BUD equivalent n/a 1,388.00±1,458.65 946.67±1,120.48 2,050.00±1,821.17
Oral corticosteroids (no.) n/a 1 0 1
Asthma severity: mild/severe n/a 6/4 4/2 2/2
FEV1 (L) 3.97±0.84 3.13±0.99 3.51±0.78 2.57±1.09*
FEV1 % predicted 100.70±7.23* 84.62±17.22 87.50±10.50 80.29±25.78*
FEV1/FVC 0.84±0.06* 0.69±0.13 0.72±0.11 0.64±0.15*
Values for age, ACT, FEV1, and FEV1/FVC ratio are presented as mean±SD. 
ACT, Asthma Control test; ICS, inhaled corticosteroid dose taken per day, expressed as dose of beclomethasone (μg) used over 24 hours; asthma severity, according 
to GINA; n/a, non-applicable. 
*significantly different when compared with healthy subjects.
Moskwa et al.
Allergy Asthma Immunol Res. 2018 March;10(2):144-154. https://doi.org/10.4168/aair.2018.10.2.144
Volume 10, Number 2, March 2018
146  http://e-aair.org
allergens. Patient characteristics are presented in Table 1. Nine 
healthy volunteers aged 31.78±14.62 with no previous history 
of any lung disease and with negative SPTs to a panel of inhaled 
allergens served as healthy controls. The study was approved 
by the local Bioethics Committee, and all study subjects provid-
ed informed consent.
Bronchial epithelial cell tissue culture
HBECs were grown from brushings of the bronchial tree dur-
ing bronchoscopy. HBECs were cultured as monolayer in hor-
mone-supplemented, serum-free bronchial epithelial growth 
medium (Lonza Inc., Allendale, NJ, USA). Cells were confirmed 
as epithelial by cytokeratin 19 staining and flow cytometry. Cells 
were split when confluent and seeded for experimentation at 
passage 2. HBECs were infected with RV1B or PIV3 (multiplicity 
of infection 0.1) for 1 hour. Virus was then removed, and cells 
were washed 3 times and replaced by fresh medium. After that, 
cells were harvested at 8, 24, and 48 hours. As a negative con-
trol, cells were treated with medium alone. 
RNA isolation and quantitative PCR
Total RNA was extracted from cells with the RNeasy MiniKit 
(Qiagen, Germantown, MD, USA). Then, cDNA was tran-
scribed using the RevertAid H Minus First Strand cDNA Syn-
thesis Kit (ThermoFisher Scientific, Waltham, MA, USA), fol-
lowed by quantification of target mRNA using the TaqMan Uni-
versal PCR Master Mix (ThermoFisher Scientific). Expression of 
RV1B mRNA was quantified using the PrimerDesign Genesis 
Kit for Human RV1B, and expression of PIV3 mRNA was quan-
tified using the PrimerDesign Genesis Kit for Human HPIV3 
(Genesig Ltd, Lafayette, PA, USA). Relative expression of the fol-
lowing genes was quantified by the comparative CT (ΔΔCT) 
method using 18S rRNA as a reference gene: IFN-α, IFN-β, 
IFN-λ1 (IL-29), RANTES (CCL5), IP-10 (CXCL10), and IRF-3/
IRF-7. Reactions were analyzed with the StepOnePlus Real-
Time PCR System (ThermoFisher Scientific) at 50°C for 2 min-
utes, 95°C for 10 minutes, and 45 cycles of 95°C for 15 seconds 
and 60°C for 15 seconds. Each gene was normalized to 18S 
rRNA. Real-time RT-PCR was carried out using specific primers 
and probes for each gene (Table 2).
Measurement of IFN and chemokine protein
IFN-β (PBL Assay Science) and IFN-λ1 (eBioscience, San Di-
ego, CA, USA) were measured by ELISA according to the man-
ufacturer’s instructions. The sensitivities of these assays were 50 
and 15.6 pg/mL, respectively. The concentrations of IFN-α, IP-
10, and RANTES in the culture supernatants were measured 
using BD Cytometric Bead Array (CBA) (Becton, Dickinson Co., 
Franklin Lakes, NJ, USA). The sensitivity of this assay was 10 pg/
mL each. 
Statistical analysis
All statistical analyses were performed with Statistica 10 
(AXAP301E504323AR-B). Medians (interquartile ranges) were 
used instead of means (SDs) if data were non-normally distrib-
uted. Normality was tested with the Kolmogorov-Smirnov test 
with Lilliefors correction and the Shapiro-Wilk test. Student t 
test, the Mann-Whitney test, or the Kruskal-Wallis test with 
Dunn’s multiple corrections test were used to determine differ-
ences in antiviral responses between the groups as appropriate. 
Correlations were analyzed using the Spearman rank test. A P 
value of <0.05 was considered statistically significant. 
RESULTS
PIV3 and RV1B replication in HBECs 
PIV3 mRNA was detected in cell lysates of HBECs from both 
asthmatic patients and healthy controls at all time points (8, 24, 
and 48 hours) after infection (but not in control, non-infected 
cells) (Fig. 1A and B). A significant increase in PIV3 gene copy 
number at 48 hours compared to 24 hours was observed only 
in asthmatic patients (P<0.05). RV1B mRNA was detected in 
HBECs from both groups at all time points after infection (but 
not in control, non-infected cells), and the RV1B gene copy 
number was increased in subjects of both groups reaching sig-
nificance at 48 hours compared to 8 hours (P<0.05). The Repli-
cation rate of either PIV3 or RV1B in HBECs was not significant-
ly different between subjects with and without asthma at any 
time point. Since virus replication was assessed only in 5 asth-
matics, we could not compare atopic vs non-atopic asthmatics. 
Table 2. Primer and probe sequences for use in real-time RT-PCR
Gene Sequence (5’-3’)
IFN-α Forward – 5´-CAG AGT CAC CCA TCT CAG CA-3´ 
Reverse – 5´-CAC CAC CAG GAC CAT CAG TA-3´
Probe – 5´-FAM ATC TGC AAT ATC TAC GAT GGC CTC GCC 
TAMRA-3´
IFN-β Forward – 5´-CGC CGC ATT GAC CAT CTA-3´
Reverse – 5´-GAC ATT AGC CAG GAG GTT CTC A-3´
Probe – 5´-FAM TCA GAC AAG ATT CAT CTA GCA CTG GCT 
GGA TAMRA-3´
IFN-λ1 (IL-29) Forward – 5´-GGA CGC CTT GGA AGA GTC ACT-3´
Reverse – 5´-AGA AGC CTC AGG TCC CAA TTC-3´ 
Probe – 5´-FAM AGT TGC AGC TCT CCT GTC TTC CCC G 
TAMRA-3
IRF3 Hs01547283_m1 (Life Technologies)
IRF7 Hs01014809_g1 (Life Technologies)
CCL5 (RANTES) Hs00982282_m1 (Life Technologies)
CXCL10 (IP-10) Hs00171042_m1 (Life Technologies)
18S rRNA 4352930E (Life Technologies)
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IFN generation in response to virus infection in HBECs from 
patients with asthma and in healthy controls
PIV3 and RV1B infection induced a significant IFN-λ1 protein 
increase in cell supernatants from asthmatics as well as healthy 
controls (Fig. 2A and C). There was no significant difference be-
tween healthy controls and asthmatics in the amount of IFN-λ1 
protein released, at any time point. IFN-λ1 mRNA expression 
was significantly induced by PIV3 infection in patients with 
Fig. 1. PIV3 (A) and RV1B (B) replication in HBECs from asthmatic patients (n=5) and healthy controls (n=5). Horizontal line indicates the median.
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asthma at all time points compared to medium control (Fig. 
2B). PIV3 induced IFN-λ1 mRNA expression in asthmatics, but 
not significantly in healthy controls. Infection with RV1B in-
duced IFN-λ1 mRNA expression in both subjects with asthma 
and healthy individuals (Fig. 2D). There was no difference in 
the magnitude of virus-induced mRNA expression between 
asthmatics and healthy controls for either virus. 
IFN-α and IFN-β proteins were not detectable in cell superna-
tants after either PIV3 or RV1B infection. Both viruses induced 
IFN-α mRNA expression at 48 post infection in subjects with 
asthma, but not in healthy controls. Following PIV3 infection 
IFN-β mRNA expression was significantly induced only in asth-
matic patients at 48 hours, but RV1B induced IFN-β mRNA in 
both study groups at 24 hours (P<0.05) and 48 hours (P<0.01). 
There was no significant difference between subjects with and 
without asthma in IFN-α or IFN-β mRNA expression after either 
PIV3 or RV1B infection.
Expression of IRFs
We next assessed the expression of IRF-3 and IRF-7 in virus-
infected bronchial epithelial cells. In parallel with IFN-λ1 re-
lease, there was significant induction of IRF-7 mRNA by both 
PIV3 and RV1B at all time points without difference between 
asthmatics and healthy controls (Fig. 3A and B). We did not ob-
serve IRF-3 expression after infection with either of the viruses 
(data not shown).
There was a strong positive correlation between IRF-7 mRNA 
of and IFN-λ1 mRNA expression in both healthy controls and 
asthmatic following PIV3 infection, while after RV1B infection 
such correlation was observed only in healthy controls. Inter-
estingly after RV1B infection, a correlation between IRF-7 and 
IFN-β gene expression was observed in asthmatics at 24 hours 
(r=0.63, P<0.05) and 48 hours (r=0.73, P<0.05).
IP-10 and RANTES generation in response to virus infection in 
HBECs from patients with asthma and in healthy controls
PIV3 induced significant release of IP-10 protein into cell su-
pernatants of HBECs in both healthy controls and asthmatics; 
however, HBECs from asthmatics produced significantly more 
IP-10 protein at 24 hours (median 1,296.65 pg/mL [256.17-
5,740.30]) and 48 hours (median 4,119.34 pg/mL [421.82-
9,366.14]) compared to HBECs from healthy controls (64.64 pg/
mL [45.91-91.12], 111.24 pg/mL [64.57-514.52]) at 24 and 48 
hours, respectively (P<0.05) (Fig. 4A). In parallel, IP-10 mRNA 
expression was significantly higher (median 8.26-fold) in asth-
matics (572.51 [216.77-1,078.64]) compared to HBECs from 
healthy controls (61.83 [18.31-302.85], P<0.05) at 48 hours (Fig. 
4B). RV1B infection induced IP-10 release at 24 and 48 hours 
(P<0.01) in both groups and a trend toward higher expression 
of IP-10 mRNA was observed in asthmatics (Fig. 4C and D). 
Both PIV3 and RV1B infection induced significant (P<0.01) 
RANTES release, which was similar in epithelial cells from both 
groups (data not shown).
IFN generation in response to virus infection in HBECs from 
atopic and non-atopic asthmatics
In patients with non-atopic asthma (n=4), IFN-λ1 protein 
production in response to PIV3 was supressed at 24 and 48 
hours, which was significantly lower (P<0.05) compared to 
subjects with atopic asthma (n=6) (Fig. 5A). The IFN-λ1 protein 
level in response to PIV3 in atopic asthmatics was significantly 
higher at 48 hours compared to non-atopic asthmatics 
(5.60-times) and healthy controls (29.09-fold) (Fig. 5A). IFN-λ1 
mRNA expression was significantly higher in atopic asthmatics 
at 8 hours compared to non-atopic asthmatics and healthy con-
trols and at 48 hours post infection compared to healthy con-
trols (Fig. 5B). In atopic asthmatics (but not in non-atopic), 
IFN-β mRNA induction by PIV3 was significantly higher com-
pared to healthy controls at all time points (Fig. 5C). No differ-
ence in IFN-α mRNA expression of HBECs between patients 
with atopic or non-atopic asthma was observed. 
IRF-7 mRNA induction was significantly lower in HBECs from 
non-asthmatics compared to those from atopic asthmatics at 8 
and 24 hours (P<0.01) post PIV3 infection; however, only in 
Fig. 3. IRF7 mRNA expression in HBECs post PIV3 (A) and RV1B (B) infection in asthmatic patients (n=10) and healthy controls (n=9). Significant induction in HBECs 
by PIV3 and RV1B. *P<0.05, **P<0.01 compared to medium control.
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atopic asthmatics PIV3 induced IRF-7 mRNA expression was 
higher compared to healthy controls at 8 and 24 hours (P<0.05) 
after infection (Fig. 5D). 
Following RV1B infection, atopic asthmatics had significantly 
higher IFN-β mRNA expression at 24 hours (P<0.05) and 48 
hours (P<0.01) compared to non-atopic asthmatics; however, 
no significant differences between groups were observed with 
respect to IFN-λ1 protein generation or IFN-λ1, IFN-α, and IRF-
7 mRNA expressions (data not shown).
IP-10 and RANTES generation in response to virus infection in 
HBECs from atopic and non-atopic asthmatics
Following PIV3 infection, RANTES protein levels (but not 
mRNA expressions) in non-atopic asthmatic patients were sig-
nificantly lower at 8 hours (median 0.40 [0.34-0.49] pg/mL) 
compared to atopic asthmatics (median 8.87 [5.50-16.87] pg/
mL, P<0.01) or healthy subjects (median 10.29 [3.65-19.22] pg/
mL, P<0.01). However, there was no significant difference be-
tween .atopic and non-atopic asthmatic patients in IP-10 pro-
tein synthesis or IP-10 mRNA expression at any time point (data 
not shown). Following RV1B infection, there was no difference 
in IP-10 or RANTES (protein or mRNA) expression between 
atopic and non-atopic asthmatics (data not shown).
Immune response to virus infection in HBECs from patients 
with severe and non-severe asthma
Patients with severe asthma, defined according to the GINA 
criteria, had significantly lower ACT (11.75±2.75) compared to 
non-severe asthmatics (20.83±1.62, P<0.01); however, there 
was no significant difference either in PIV3 or RV1B induced 
IFN-λ1 protein and mRNA or in IFN-α and IFN-β mRNA ex-
pressions in HBECs between asthmatics with severe (n=4) and 
non-severe asthma (n=6). Expression of IRF-7 was similar in 
both groups. There was no difference in IP-10 or RANTES pro-
tein level or gene expression after infection with either virus be-
tween patients with severe or non-severe asthma.
DISCUSSION
Over the last decade, deficient innate immune response (in-
cluding IFN production) to virus infection in HBECs from pa-
tients with asthma has been observed since the original report 
Fig. 4. IP-10 protein (A) and mRNA expression (B) in HBECs post PIV3 infection and IP-10 protein (C) and mRNA expression (D) in HBECs post RV1B infection in asth-
matic patients (n=10) and healthy controls (n=9). Significant induction in HBECs by PIV3 and RV1B. *P<0.05, **P<0.01 compared to medium control.
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by Wark et al.,9 but it has not been confirmed in all the studies. 
Most reported studies employed a single virus (usually one of 
the RVs) and these studies differed in the experimental tech-
nique, including culture method, virus load, and clinical char-
acteristics of the subjects, which may be responsible for the con-
flicting results. In this study, we assessed in parallel innate im-
mune response to 2 respiratory viruses (PIV3 and RV1B) in pri-
mary HBECs cultured from a phenotypically heterogeneous, 
but well characterized group of asthma patients and healthy 
controls. 
Initially, we demonstrated that the viral replication rates for 
both PIV3 and RV1B in HBECs from asthmatic patients and 
healthy controls were not different. Our observation is in line 
with other in vitro studies.21,22,24 However, other studies showed 
increased RV replication in asthmatic HBECs ex vivo9,11,16,17 and 
in vivo using experimental virus challenge.38,39 Similarly, Patel et 
al.25 documented higher levels of influenza A virus protein, but 
not RSV in HBECs from asthmatics compared to healthy con-
trols. 
Furthermore, we did not find any quantitative difference be-
tween asthmatic patients and healthy controls in the magni-
tude of IFN response to either virus. Consequently, IRF-7, an 
inducible interferon-stimulated gene in bronchial epithelial 
cells, was increased in parallel with the infection and was aug-
mented to a similar extent in both groups. Previous studies re-
ported type I or III IFN induction in primary HBECs of asthmat-
ic patients in response to RV infection lower9,11,12,16,17 or the 
same21,22,24,25 compared to healthy controls. Impaired immune 
responses were also observed in HBECs stimulated with viral 
dsRNA.40,41 Although deficient IFN type I and III response has 
been identified in PBMCs from pregnant female asthmatics in-
fected with RV-43 or RV1B, no difference was observed be-
tween non-pregnant female asthmatics and non-pregnant 
healthy females.42 In a recent study, Sykes et al.24 showed that in 
relatively mild and well-controlled asthmatics, IFN production 
in HBECs in response to RV16 was not impaired. Contradictory 
results of studies reporting either virus replication or IFN re-
sponses to virus infections in patients with asthma may reflect 
the phenotypic heterogeneity of the disease, reflected also by 
variability in the innate immune response. Our asthmatic pa-
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tients were quite heterogeneous to some clinical traits, such as 
presence of atopic sensitization or severity of the disease. Thus, 
in order to gain some insight into the potential role of host fac-
tors on ability of HBECs to respond to viral infections, asthmat-
ic patients were stratified according to pathophysiological and 
clinical phenotypes. Compared to atopic patients, HBECs from 
subjects with non-atopic asthma had significantly diminished 
overall immune response to PIV3. At 48 hours post infection, 
IFN-λ1 protein was barely detectable in supernatants of HBECs 
from non-atopic asthmatics, while in atopic asthmatics its level 
was very high (median 660.04 pg/mL) and significantly higher 
compared to healthy controls. Differences in IFN-λ1 protein re-
lease between non-atopic and atopic asthmatics were paral-
leled by a similar pattern of IFN-λ1 mRNA expression. Although 
IFN-β protein was not detectable, there was a transient increase 
in IFN-β mRNA expression in atopic asthmatics at 8 hours post 
infection with PIV3 compared to non-atopic asthmatics. Im-
pairment in IFN expression in non-atopic asthmatics was par-
alleled by a decrease in expression of IRF-7 with significant dif-
ferences from atopics at 8 and 24 hours after PIV3 infection. In 
contrast, chemokine (IP-10 and RANTES) release did not differ 
between atopic and non-atopic asthmatics. 
In response to RV1B, no difference in IFN, IRF, or chemokine 
expression between atopic and non-atopic asthma patients 
were observed, with the exception of IFN-β mRNA, which was 
significantly lower in non-atopic asthmatics. The lack of differ-
ence between atopic and non-atopic asthmatics in IFN-λ1 re-
lease and expression in response to RV1B may result from differ-
ent pathophysiological mechanisms of epithelial immune re-
sponse to different viruses.43,44 Alternatively, it is possible that the 
difference was not detected due to significantly weaker overall 
immune response of epithelial cells to RV1B compared to PIV3; 
the experiments should be repeated with higher RV MOIs.
Our results suggest that non-atopic status of asthma patients 
which is distinguished by lack of allergic sensitisation may be 
associated with impaired IFN (but not other chemokines like 
RANTES) response to virus infection. In contrast, in atopic 
asthmatics IFN-λ1 and IFN-β response to PIV3 infection was ei-
ther comparable or even more intense compared to healthy 
controls. Non-atopic asthma is not a well-characterized pheno-
type and is rather diagnosed by exclusion of atopic sensitiza-
tion. The inflammatory process in the airways seems to be very 
similar between allergic and non-allergic asthma based on the 
expression of inflammatory mediators, including Th2 cytokines 
and eosinophilotactic chemokines, but prevailing triggering 
factors seem to be different.45 On the other hand, a significant 
heterogeneity of asthma may involve different inflammatory 
phenotypes, some of which may differ in terms of innate im-
mune activation during viral infection.46 Our observations doc-
umenting impaired IFN responses to viral infection in a sub-
population of asthma patients are in line with well-established 
non-atopic asthma phenotype, which includes respiratory in-
fections as dominant exacerbation-triggering factors.47 A recent 
systematic review documented association of non-atopic asth-
ma/wheeze with lower respiratory tract infections in children 
and adolescents.48 Interestingly, non-atopic asthmatics are 
more likely to have respiratory pathogens detected in nasopha-
ryngeal swabs during asthma exacerbation.49 Thus, further 
studies are necessary to establish the immune response in 
atopic asthmatics compared to non-atopic asthmatics.
However, a significant limitation of this analysis is related to 
relatively small sample size, with 6 participants in atopic and 4 
in non-atopic asthmatic and further heterogeneity within sub-
groups. The differences were not related to asthma control or 
severity, since asthma control test and overall severity accord-
ing to GINA criteria or maintenance dose of inhaled corticoste-
roids were similar in atopic and not atopic asthma patients. 
However, non-atopic asthmatics were on average older and had 
significantly lower respiratory function parameters compared 
to atopic asthmatics, which may have affected immune re-
sponse to viral infection. These results cannot be easily referred 
to other studies assessing antiviral response in HBECs, since in 
earlier studies either only atopic asthmatics were recruit-
ed9,11,17,21,22,24 or patients’ atopic status was not reported.12 The 
antiviral response to respiratory virus in patients with atopic 
and non-atopic asthma was reported by Baraldo et al.16 who 
demonstrated impaired expression of IFN-β gene after infection 
with RV16 in children with asthma compared to controls. At the 
same time, they did not find any differences in the antiviral re-
sponse between children with atopic and non-atopic asthma. 
Although generation of IFNs and RANTES in response to in-
fection with PIV3 or RV1B was similar in the whole group of 
asthmatics and healthy controls, significant differences were ob-
served with respect to IP-10 production. Upon PIV3 infection, 
patients with asthma expressed significantly more IP-10 both at 
protein and mRNA level than healthy controls. A similar trend 
toward higher expression of IP-10 was also observed after RV1B 
infection; however, the difference was not statistically signifi-
cant. IFN-γ-IP-10 (CXCL10) belongs to the CXC chemokine sub-
family that binds to common CXCR3 receptor and is produced 
by various cell types, including airway epithelial cells in re-
sponse to viral infection.50 Previously, significantly increased se-
rum IP-10 levels were observed in subjects with acute virus-in-
duced asthma compared to non-virus-induced acute or con-
trolled asthma,32,33 and RV-infected human airway epithelial 
cells produce IP-10 in vitro and in vivo.31 However, Wark et al.32 
did not observe significant differences in IP-10 serum levels in 
asthmatic patients compared to healthy volunteers. Similarly, 
no differences in IP-10 release by nasal epithelial cells and tra-
cheal epithelial cells from children with wheeze/atopy in re-
sponse to RSV or hMPV infection were observed.56 IP-10 is 
thought to play an important role in the Th1-mediated immune 
response, but it has been implicated also in exacerbation of Th2-
mediated airway inflammation typical for bronchial asthma.51,52 
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Th2 cytokines increase release of IP-10 and other inflammatory 
cytokines in the presence of RV infection.53 Since there is evi-
dence that IP-10 is generated downstream to IFNs and that 
IFN-λ can also induce IP-10 production, elevated IP-10 genera-
tion (but not IFN production) in asthma patients might be relat-
ed to other mechanisms and warrant further investigation. 
Comparing immune/inflammatory response between differ-
ent respiratory viruses is controversial, since even different RV 
strains can induce different patterns of cytokines and chemo-
kines.54,55 Thus, it is important to assess innate immune response 
to various respiratory pathogens in asthmatics. Previous stud-
ies reported innate response to several respiratory viruses e.g. 
RV, RSV,25,26 hMPV,56 and influenza A25,57 in airway epithelial cells 
from asthmatic patients, but this is the first report documenting 
that PIV3 efficiently replicates in bronchial epithelium from 
asthmatics. The role of type III INFs in the immune response to 
PIV3 has not been studied in patients with asthma. In this study, 
we demonstrated that IFN-λ is the major IFN subtype induced 
in HBECs by PIV3 infection, similar to other respiratory virus-
es.10,22,24 As in studies with other respiratory viruses,10,24 we were 
able to detect IFN-β and IFN-α only at the mRNA level. Howev-
er, in our model PIV3 and RV1B induced type I INFs only in pa-
tients with asthma (data not shown).
The increase in IFN production by PIV3 and RV1B was associ-
ated with parallel induction of IRF-7 mRNA which was ob-
served as early as 8 hours post infection and sustained up to 48 
hours. IRF-7 mRNA expression following PIV3 infection highly 
correlated with IFN-λ1 expression in both healthy controls and 
asthmatics, while after RV1B infection a significant correlation 
was observed only in healthy controls. On the other hand, IRF-
7 expression correlated with IFN-β expression in response to 
both viruses in asthmatics patients and after RV1B only in asth-
matics. As expected, expression of IRF-3 mRNA in HBECs in-
fected with respiratory viruses was not changed, since activa-
tion of IRF-3 is associated with increased phosphorylation rath-
er than changes in expression.
In summary, this is the first report documenting that PIV3 ef-
ficiently replicates in primary HBECs from patients with asth-
ma and that IFN-λ1 release and expression in epithelial cells, 
which are associated with IRF-7 expression, are pivotal to the 
antiviral response. However, the most intriguing observation is 
the modulatory effect of atopy on the impaired generation of 
INFs in the airway epithelium of asthmatic patients in response 
to virus infection. Further studies are warranted to confirm if 
such an effect can be observed with other viruses and to eluci-
date the significance of this phenomenon in the pathogenesis 
of respiratory virus infections in asthmatic patients.
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